Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Clinical trials
Innovation: Pipeline overview
Novartis pipeline in Phase 2
Solid Tumors
Code
AAA601
Name
LutatheraⓇ
Mechanism
Indication(s)
Radioligand therapy target SSTR GEPNET, pediatrics
Ad2AR inhibitor, PD1 inhibitor
JDQ443 JDQ443
KRAS inhibitor
NIR178
NIS793 NIS793
TNO155 TNO155
NIR178, spartalizumab
TGFB inhibitor
SHP2 inhibitor
1L ES-SCLC
Glioblastoma
NSCLC (Combo)
Cancers
1L metastatic colorectal cancer
Solid tumors (single agent)
References
Abbreviations
27 lead indications
Lead indication
Hematology
Code
Name
ABL001 ScemblixⓇ
INC424 JakaviⓇ
LNP023 iptacopan
MBG453 sabatolimab
PHE885 PHE885
PKC412 Rydapte
Cardiovascular
Mechanism
BCR-ABL inhibitor
JAK1/2 inhibitor
CFB inhibitor
TIM3 antagonist
BCMA cell therapy
Multi-targeted kinase inhibitor
Indication(s)
Chronic myeloid leukemia, 2L, pediatrics
Acute GVHD, pediatrics
Immune thrombocytopenia
Unfit acute myeloid leukaemia
Acute myeloid leukaemia, maintenance
4L multiple myeloma
Acute myeloid leukemia, pediatrics
Chronic GVHD, pediatrics
Immunology
Name
Code
Mechanism
Indication(s)
CFZ533
iscalimab
CD40 inhibitor
CMK389
CMK389
IL-18 inhibitor
DFV890 DFV890
NLRP3 inhibitor
Sjögren's
Atopic dermatitis
Osteoarthritis
Familial cold auto-inflammatory syndrome
LNA043 LNA043
ANGPTL3 agonist
Knee osteoarthritis
Osteoarthritis (combos)
Hidradenitis suppurativa
Code Name
CFZ533 iscalimab
HSY244 HSY244
LNP023 iptacopan
Mechanism
CD40 inhibitor
CFB inhibitor
MBL949 MBL949
TIN816 TIN816
ATP modulator
LOU064
remibrutinib
BTK inhibitor
Food allergy
Hidradenitis suppurativa
Others
Sjögren's
LRX712 LRX712
Osteoarthritis
Code
Name
Mechanism
LYS006 LYS006
Anti-inflammatory
Colitis ulcerative
Global Health
MAS825 MAS825
MHV370 MHV370
NLRC4-GOF indications
Sjögren's
Hidradenitis suppurativa
KAE609
Mixed connective tissue disease
KAF156
cipargamin
ganaplacide
PfATP4 inhibitor
VAY736 ianalumab
BAFF-R inhibitor
Autoimmune hepatitis
LXE408
Systemic lupus erythematosus
SEG101
SKO136
LXE408
AdakveoⓇ
ensovibep
Respiratory & Allergy
Neuroscience
Code
ADPT06 ADPT06
CMK389
Name
Mechanism
Indication(s)
LTP001
Cognitive impairment
QMF149
CMK389
LTP001
AtecturaⓇ
IL-18 inhibitor
SMURF1 inhibitor
Combo
BLZ945
DLX313
LMI070
sotuletinib
DLX313 (UCB0599)
branaplam
CSF-1R inhibitor
Amyotrophic lateral sclerosis
Ophthalmology
Alpha-synuclein Inhibitor
mRNA splicing modulator
Parkinson's disease
LKA651
Huntington's disease²
LNP023
LKA651
iptacopan
EPO inhibitor
CFB inhibitor
MIJ821
MIJ821
NR2B negative allosteric
modulator
Major depressive disorder with acute suicidal ideation or behavior
PPY9881
PPY988
Gene therapy
SAF312
Libvatrep
TRPV1 antagonist
1. Gyroscope acquisition.
2. Plan update ongoing.
38 Investor Relations | Q3 2022 Results
Indication(s)
Lupus nephritis Type 1 diabetes mellitus
Atrial fibrillation
Membranous nephropathy
Lupus nephritis
Obesity related diseases
Acute kidney injury
Proteasome inhibitor
P-selectin inhibitor
Multi-specific DARPin
Indication(s)
Malaria, uncomplicated
Malaria, severe
Malaria, uncomplicated
Visceral leishmaniasis
Sickle cell disease, pediatrics
Corona virus infection
Pulmonary sarcoidosis
PAH
Asthma, pediatrics
Diabetic retinopathy
iAMD
Geographic atrophy
Chronic ocular surface pain
U NOVARTIS | Reimagining MedicineView entire presentation